{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:06:42Z","timestamp":1787026002523,"version":"build-2736575974"},"reference-count":86,"publisher":"National Institute for Health and Care Research","issue":"63","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["16\/15\/03"],"award-info":[{"award-number":["16\/15\/03"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Around one-third of pregnant women suffer from moderate to severe nausea and vomiting, causing physical and emotional distress and reducing their quality of life. There is no cure for nausea and vomiting in pregnancy. Management focuses on relieving symptoms and preventing morbidity, and often requires antiemetic therapy. National guidelines make recommendations about first-, second- and third-line antiemetic therapies, although care varies in different hospitals and women report feeling unsupported, dissatisfied and depressed.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To determine whether or not, in addition to intravenous rehydration, ondansetron compared with no ondansetron and metoclopramide compared with no metoclopramide reduced the rate of treatment failure up to 10 days after drug initiation; improved symptom severity at 2, 5 and 10 days after drug initiation; improved quality of life at 10 days after drug initiation; and had an acceptable side effect and safety profile. To estimate the incremental cost per treatment failure avoided and the net monetary benefits from the perspectives of the NHS and women.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n This was a multicentre, double-dummy, randomised, double-blinded, dummy-controlled 2\u2009\u00d7\u20092 factorial trial (with an internal pilot phase), with qualitative and health economic evaluations.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n Thirty-three patients (who were <\u200917 weeks pregnant and who attended hospital with nausea and vomiting after little or no improvement with first-line antiemetic medication) who attended 12 secondary care NHS trusts in England, 22 health-care professionals and 21 women participated in the qualitative evaluation.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomly allocated to one of four treatment groups (1\u2009:\u20091\u2009:\u20091:\u20091 ratio): (1) metoclopramide and dummy ondansetron; (2) ondansetron and dummy metoclopramide; (3) metoclopramide and ondansetron; or (4) double dummy. Trial medication was initially given intravenously and then continued orally once women were able to tolerate oral fluids for a maximum of 10 days of treatment.<\/jats:p>\n <\/jats:sec>\n \n Main outcome measures<\/jats:title>\n The primary end point was the number of participants who experienced treatment failure, which was defined as the need for further treatment because symptoms had worsened between 12 hours and 10 days post treatment. The main economic outcomes were incremental cost per additional successful treatment and incremental net benefit.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 592 patients screened, 122 were considered eligible and 33 were recruited into the internal pilot (metoclopramide and dummy ondansetron,\n n<\/jats:italic>\n \u2009=\u20098; ondansetron and dummy metoclopramide,\n n<\/jats:italic>\n \u2009=\u20098; metoclopramide and ondansetron,\n n<\/jats:italic>\n \u2009=\u20098; double dummy,\n n<\/jats:italic>\n \u2009=\u20099). Owing to slow recruitment, the trial did not progress beyond the pilot. Fifteen out of 30 evaluable participants experienced treatment failure. No statistical analyses were performed. The main reason for ineligibility was prior treatment with trial drugs, reflecting an unpredicted change in prescribing practice at several points along the care pathway. The qualitative evaluation identified the requirements of the study protocol, in relation to guidelines on anti-sickness drugs, and the diversity of pathways to care as key hurdles to recruitment while the role of research staff was a key enabler. No important adverse events or side effects were reported.\n <\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n The pilot trial failed to achieve the recruitment target owing to unforeseen changes in the provision of care.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The trial was unable to provide evidence to support clinician decisions about the best choice of second-line antiemetic for nausea and vomiting in pregnancy.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n Current Controlled Trials ISRCTN16924692 and EudraCT 2017-001651-31.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n \n This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in\n Health Technology Assessment<\/jats:italic>\n ; Vol. 25, No. 63. See the NIHR Journals Library website for further project information.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hta25630","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T04:50:16Z","timestamp":1637038216000},"page":"1-116","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT"],"prefix":"10.3310","volume":"25","clinical-trial-number":[{"clinical-trial-number":"isrctn16924692","registry":"10.18810\/isrctn","type":"results"},{"clinical-trial-number":"2017-001651-31","registry":"10.18810\/euctr","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7897-7987","authenticated-orcid":true,"given":"Stephen","family":"Robson","sequence":"first","affiliation":[{"name":"Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4144-8218","authenticated-orcid":true,"given":"Catherine","family":"McParlin","sequence":"additional","affiliation":[{"name":"Department of Nursing, Midwifery and Health, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6260-3734","authenticated-orcid":true,"given":"Helen","family":"Mossop","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1703-283X","authenticated-orcid":true,"given":"Mabel","family":"Lie","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-225X","authenticated-orcid":true,"given":"Cristina","family":"Fernandez-Garcia","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0033-548X","authenticated-orcid":true,"given":"Denise","family":"Howel","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9432-760X","authenticated-orcid":true,"given":"Ruth","family":"Graham","sequence":"additional","affiliation":[{"name":"School of Geography, Politics and Sociology, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7056-298X","authenticated-orcid":true,"given":"Laura","family":"Ternent","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-1455","authenticated-orcid":true,"given":"Alison","family":"Steel","sequence":"additional","affiliation":[{"name":"Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1211-936X","authenticated-orcid":true,"given":"Nicola","family":"Goudie","sequence":"additional","affiliation":[{"name":"Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2739-8130","authenticated-orcid":true,"given":"Afnan","family":"Nadeem","sequence":"additional","affiliation":[{"name":"Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1358-4223","authenticated-orcid":true,"given":"Julia","family":"Phillipson","sequence":"additional","affiliation":[{"name":"Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9390-1489","authenticated-orcid":true,"given":"Manjeet","family":"Shehmar","sequence":"additional","affiliation":[{"name":"Gynaecology Secretaries Department, Birmingham Women\u2019s and Children\u2019s NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-7583","authenticated-orcid":true,"given":"Nigel","family":"Simpson","sequence":"additional","affiliation":[{"name":"Leeds Institute of Medical Research, Department of Women\u2019s and Children\u2019s Health, School of Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7936-8876","authenticated-orcid":true,"given":"Derek","family":"Tuffnell","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8002-6953","authenticated-orcid":true,"given":"Ian","family":"Campbell","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9228-0972","authenticated-orcid":true,"given":"Rew","family":"Williams","sequence":"additional","affiliation":[{"name":"Patient representative"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9812-5183","authenticated-orcid":true,"given":"Margaret E","family":"O\u2019Hara","sequence":"additional","affiliation":[{"name":"Patient representative"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8300-3204","authenticated-orcid":true,"given":"Elaine","family":"McColl","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9311-1196","authenticated-orcid":true,"given":"Catherine","family":"Nelson-Piercy","sequence":"additional","affiliation":[{"name":"Department of Obstetric Medicine, Guy\u2019s and St Thomas\u2019 Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2021,11]]},"reference":[{"key":"key2021111609244511_ref1-bib1","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMcp1003896","article-title":"Clinical practice. Nausea and vomiting in pregnancy","volume":"363","author":"Niebyl","year":"2010","journal-title":"N Engl J Med"},{"key":"key2021111609244511_ref1-bib2","doi-asserted-by":"publisher","first-page":"d3606","DOI":"10.1136\/bmj.d3606","article-title":"Management of nausea and vomiting in pregnancy","volume":"342","author":"Jarvis","year":"2011","journal-title":"BMJ"},{"key":"key2021111609244511_ref1-bib3","first-page":"e171","article-title":"Quantifying the global rates of nausea and vomiting of pregnancy: a meta analysis","volume":"20","author":"Einarson","year":"2013","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"key2021111609244511_ref1-bib4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3109\/01674820109049946","article-title":"Factors associated with elective termination of pregnancy among Canadian and American women with nausea and vomiting of pregnancy","volume":"22","author":"Mazzotta","year":"2001","journal-title":"J Psychosom Obstet Gynaecol"},{"key":"key2021111609244511_ref1-bib5","doi-asserted-by":"publisher","first-page":"e27678","DOI":"10.1371\/journal.pone.0027678","article-title":"A prospective cohort study investigating associations between hyperemesis gravidarum and cognitive, behavioural and emotional well-being in pregnancy","volume":"6","author":"McCarthy","year":"2011","journal-title":"PLOS ONE"},{"key":"key2021111609244511_ref1-bib6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.midw.2006.12.001","article-title":"Women\u2019s responses to nausea and vomiting in pregnancy","volume":"24","author":"Locock","year":"2008","journal-title":"Midwifery"},{"key":"key2021111609244511_ref1-bib7","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1111\/j.1471-0528.2011.03023.x","article-title":"Consequences of hyperemesis gravidarum for offspring: a systematic review and meta-analysis","volume":"118","author":"Veenendaal","year":"2011","journal-title":"BJOG"},{"key":"key2021111609244511_ref1-bib8","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.3399\/bjgp18X700745","article-title":"Nausea and vomiting of pregnancy and resource implications: the NVP Impact Study","volume":"69","author":"Gadsby","year":"2019","journal-title":"Br J Gen Pract"},{"key":"key2021111609244511_ref1-bib9","volume-title":"Hospital Episode Statistics, Admitted Patient Care, England \u2013 2013\u201314","author":"NHS Digital","year":"2015"},{"key":"key2021111609244511_ref1-bib10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/AOG.0000000000000982","article-title":"The most commonly dispensed prescription medications among pregnant women enrolled in the U.S. Medicaid program","volume":"126","author":"Palmsten","year":"2015","journal-title":"Obstet Gynecol"},{"key":"key2021111609244511_ref1-bib11","first-page":"520","article-title":"Changing attitudes and perceptions to hyperemesis gravidarum","volume":"6","author":"Soltani","year":"2003","journal-title":"RCM Midwives"},{"key":"key2021111609244511_ref1-bib12","volume-title":"The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum","author":"Royal College of Obstetricians and Gynaecologists","year":"2016"},{"issue":"74","key":"key2021111609244511_ref1-bib13","doi-asserted-by":"publisher","DOI":"10.3310\/hta20740","article-title":"Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: a systematic review and economic assessment","volume":"20","author":"O\u2019Donnell","year":"2016","journal-title":"Health Technol Assess"},{"key":"key2021111609244511_ref1-bib14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007575.pub4","article-title":"Interventions for nausea and vomiting in early pregnancy","volume":"9","author":"Matthews","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"key2021111609244511_ref1-bib15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010607.pub2","article-title":"Interventions for treating hyperemesis gravidarum","volume":"5","author":"Boelig","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"key2021111609244511_ref1-bib16","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/AOG.0b013e3181d99290","article-title":"Promethazine compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial","volume":"115","author":"Tan","year":"2010","journal-title":"Obstet Gynecol"},{"key":"key2021111609244511_ref1-bib17","first-page":"127","article-title":"Ondansetrone or metoclopromide? Which is more effective in severe nausea and vomiting of pregnancy? A randomized trial double-blind study","volume":"40","author":"Kashifard","year":"2013","journal-title":"Clin Exp Obstet Gynecol"},{"key":"key2021111609244511_ref1-bib18","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1097\/AOG.0000000000000242","article-title":"Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial","volume":"123","author":"Abas","year":"2014","journal-title":"Obstet Gynecol"},{"key":"key2021111609244511_ref1-bib19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/01443610500060651","article-title":"Validation studies of the Pregnancy Unique-Quantification of Emesis (PUQE) scores","volume":"25","author":"Koren","year":"2005","journal-title":"J Obstet Gynaecol"},{"key":"key2021111609244511_ref1-bib20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.ajog.2007.05.051","article-title":"Validity of a modified Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) scoring index to assess severity of nausea and vomiting of pregnancy","volume":"198","author":"Lacasse","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"key2021111609244511_ref1-bib21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1067\/mob.2002.123054","article-title":"Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system for nausea and vomiting of pregnancy","volume":"186","author":"Koren","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"key2021111609244511_ref1-bib22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1477-7525-6-32","article-title":"Validation of the nausea and vomiting of pregnancy specific health related quality of life questionnaire","volume":"6","author":"Lacasse","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"key2021111609244511_ref1-bib23","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1192\/bjp.150.6.782","article-title":"Detection of postnatal depression: development of the 10-item Edinburgh Postnatal Depression Scale","volume":"150","author":"Cox","year":"1987","journal-title":"Br J Psychiatry"},{"key":"key2021111609244511_ref1-bib24","volume-title":"Manual for the State Trait Anxiety Inventory","author":"Spielberger","year":"1983"},{"key":"key2021111609244511_ref1-bib25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1046\/j.1523-536x.2000.00097.x","article-title":"Measuring social support in pregnancy: can it be simple and meaningful?","volume":"27","author":"Webster","year":"2001","journal-title":"Birth"},{"key":"key2021111609244511_ref1-bib26","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","author":"National Institutes of Health (NIH)","year":"2010"},{"key":"key2021111609244511_ref1-bib27","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0002-9378(96)70607-5","article-title":"A pilot study of intravenous ondansetron for hyperemesis gravidarum","volume":"174","author":"Sullivan","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"key2021111609244511_ref1-bib28","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/AOG.0000000000000479","article-title":"Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial","volume":"124","author":"Oliveira","year":"2014","journal-title":"Obstet Gynecol"},{"key":"key2021111609244511_ref1-bib29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejogrb.2016.02.016","article-title":"Hyperemesis in pregnancy study: a pilot randomised controlled trial of midwife-led outpatient care","volume":"200","author":"McParlin","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"key2021111609244511_ref1-bib30","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"key2021111609244511_ref1-bib31","volume-title":"Constructing Grounded Theory a Practical Guide Through Qualitative Analysis","author":"Charmaz","year":"2006"},{"key":"key2021111609244511_ref1-bib32","volume-title":"Interpreting Qualitative Data: Methods for Analyzing Talk, Text and Interaction","author":"Silverman","year":"2006"},{"key":"key2021111609244511_ref1-bib33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual ResPsychol"},{"key":"key2021111609244511_ref1-bib34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.7748\/nr2011.01.18.2.52.c8284","article-title":"Qualitative data analysis: the framework approach","volume":"18","author":"Smith","year":"2011","journal-title":"Nurse Res"},{"key":"key2021111609244511_ref1-bib35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4324\/9780203413081_chapter_9","volume-title":"Analyzing Qualitative Data","author":"Ritchie","year":"1994"},{"key":"key2021111609244511_ref1-bib36","unstructured":"Great Britain. Data Protection Act 1998. London: The Stationery Office; 1998."},{"key":"key2021111609244511_ref1-bib37","unstructured":"Great Britain. Data Protection Act 2018. London: The Stationery Office; 2018."},{"key":"key2021111609244511_ref1-bib38","unstructured":"Great Britain. National Health Service Act 2006. London: The Stationery Office; 2006."},{"key":"key2021111609244511_ref1-bib39","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/1471-0528.15662","article-title":"Clinical management of nausea and vomiting in pregnancy and hyperemesis gravidarum across primary and secondary care: a population-based study","volume":"126","author":"Fiaschi","year":"2019","journal-title":"BJOG"},{"key":"key2021111609244511_ref1-bib40","unstructured":"National Institute for Health Research (NIHR). Definition of Feasibility vs. Pilot Studies. Southampton: NIHR; 2018. URL: www.nihr.ac.uk\/documents\/nihr-research-for-patient-benefit-rfpb-programme-guidance-on-applying-for-feasibility-studies\/20474 (accessed 9 July 2020)."},{"key":"key2021111609244511_ref1-bib41","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1093\/humrep\/dew128","article-title":"Hospital admission for hyperemesis gravidarum: a nationwide study of occurrence, reoccurrence and risk factors among 8.2 million pregnancies","volume":"31","author":"Fiaschi","year":"2016","journal-title":"Hum Reprod"},{"key":"key2021111609244511_ref1-bib42","volume-title":"NHS Maternity Statistics, England 2017\u201318","author":"NHS Digital","year":"2018"},{"key":"key2021111609244511_ref1-bib43","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/1471-0528.15824","article-title":"Antiemetics in hyperemesis gravidarum: unawareness or negligence?","volume":"126","author":"Trovik","year":"2019","journal-title":"BJOG"},{"key":"key2021111609244511_ref1-bib44","volume-title":"Primary Care Management of Nausea and Vomiting In Early Pregnancy","author":"Nottinghamshire Area Prescribing Committee","year":"2020"},{"key":"key2021111609244511_ref1-bib45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/02813432.2019.1569424","article-title":"Women\u2019s perspectives on the management and consequences of hyperemesis gravidarum \u2013 a descriptive interview study","volume":"37","author":"Havnen","year":"2019","journal-title":"Scand J Prim Health Care"},{"key":"key2021111609244511_ref1-bib46","doi-asserted-by":"publisher","first-page":"e000330","DOI":"10.1136\/bmjoq-2018-000330","article-title":"Optimisation of hyperemesis gravidarum management through an emergency department setting","volume":"7","author":"Skalley","year":"2018","journal-title":"BMJ Open Qual"},{"key":"key2021111609244511_ref1-bib47","doi-asserted-by":"publisher","first-page":"24","DOI":"10.7748\/en2012.07.20.4.24.c9206","article-title":"Emergency management of hyperemesis gravidarum","volume":"20","author":"Summers","year":"2012","journal-title":"Emerg Nurse"},{"key":"key2021111609244511_ref1-bib48","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/1471-0528.16177","article-title":"What inhibits obstetricians implementing reliable guidelines?","volume":"127","author":"Bewley","year":"2019","journal-title":"BJOG"},{"key":"key2021111609244511_ref1-bib49","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1097\/01.AOG.0000236434.74160.8b","article-title":"Evidence-based strategies for implementing guidelines in obstetrics: a systematic review","volume":"108","author":"Chaillet","year":"2006","journal-title":"Obstet Gynecol"},{"key":"key2021111609244511_ref1-bib50","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(03)14546-1","article-title":"From best evidence to best practice: effective implementation of change in patients\u2019 care","volume":"362","author":"Grol","year":"2003","journal-title":"Lancet"},{"key":"key2021111609244511_ref1-bib51","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/ajo.12890","article-title":"Reported adherence to current antenatal corticosteroid guidelines in Australia and New Zealand","volume":"59","author":"Tuohy","year":"2019","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"key2021111609244511_ref1-bib52","doi-asserted-by":"publisher","first-page":"e13261","DOI":"10.1111\/ijcp.13261","article-title":"Assessment of discharge treatment prescribed to women admitted to hospital for hyperemesis gravidarum","volume":"73","author":"Fiaschi","year":"2019","journal-title":"Int J Clin Pract"},{"key":"key2021111609244511_ref1-bib53","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12884-015-0746-2","article-title":"Treatment of nausea in pregnancy: a cross-sectional multinational web-based study of pregnant women and new mothers","volume":"15","author":"Heitmann","year":"2015","journal-title":"BMC Pregnancy Childbirth"},{"key":"key2021111609244511_ref1-bib54","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/AOG.0000000000002679","article-title":"Ondansetron for treatment of nausea and vomiting of pregnancy and the risk of specific birth defects","volume":"132","author":"Parker","year":"2018","journal-title":"Obstet Gynecol"},{"key":"key2021111609244511_ref1-bib55","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000010189","article-title":"Evaluation of treatment of hyperemesis gravidarum using parenteral fluid with or without diazepam. A randomized study","volume":"48","author":"Ditto","year":"1999","journal-title":"Gynecol Obstet Invest"},{"key":"key2021111609244511_ref1-bib56","doi-asserted-by":"publisher","first-page":"e010194","DOI":"10.1136\/bmjopen-2015-010194","article-title":"Feasibility of surgical randomised controlled trials with a placebo arm: a systematic review","volume":"6","author":"Wartolowska","year":"2016","journal-title":"BMJ Open"},{"key":"key2021111609244511_ref1-bib57","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1136\/bmj.318.7191.1114","article-title":"Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study","volume":"318","author":"Welton","year":"1999","journal-title":"BMJ"},{"key":"key2021111609244511_ref1-bib58","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(19)31270-X","article-title":"Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial","volume":"394","author":"Chappell","year":"2019","journal-title":"Lancet"},{"key":"key2021111609244511_ref1-bib59","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/0197-2456(85)90121-7","article-title":"Participation in a clinical trial: the patients\u2019 point of view","volume":"6","author":"Mattson","year":"1985","journal-title":"Control Clin Trials"},{"key":"key2021111609244511_ref1-bib60","doi-asserted-by":"publisher","first-page":"e017566","DOI":"10.1136\/bmjopen-2017-017566","article-title":"Ambulatory versus inpatient management of severe nausea and vomiting of pregnancy: a randomised control trial with patient preference arm","volume":"7","author":"Mitchell-Jones","year":"2017","journal-title":"BMJ Open"},{"key":"key2021111609244511_ref1-bib61","doi-asserted-by":"publisher","first-page":"704","DOI":"10.5465\/annals.2017.0089","article-title":"Boundary work among groups, occupations and organizations: from cartography to process","volume":"13","author":"Langley","year":"2019","journal-title":"Academy Management Annals"},{"key":"key2021111609244511_ref1-bib62","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.soc.28.110601.141107","article-title":"The study of boundaries in the social sciences","volume":"28","author":"Lamont","year":"2002","journal-title":"Annual Rev Sociol"},{"key":"key2021111609244511_ref1-bib63","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1111\/1471-0528.15272","article-title":"Variation in hyperemesis gravidarum definition and outcome reporting in randomised clinical trials: a systematic review","volume":"125","author":"Koot","year":"2018","journal-title":"BJOG"},{"key":"key2021111609244511_ref1-bib64","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimisation","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"key2021111609244511_ref1-bib65","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13063-017-1870-2","article-title":"Why clinical trial outcomes fail to translate into benefits for patients","volume":"18","author":"Heneghan","year":"2017","journal-title":"Trials"},{"key":"key2021111609244511_ref1-bib66","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/1471-0528.16172","article-title":"A core outcome set for hyperemesis gravidarum research: an international consensus study","volume":"127","author":"Jansen","year":"2020","journal-title":"BJOG"},{"key":"key2021111609244511_ref1-bib67","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejogrb.2018.04.028","article-title":"Developing and validating a prognostic index predicting re-hospitalisation of patients with hyperemesis gravidarum","volume":"225","author":"Morris","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"key2021111609244511_ref1-bib68","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ygyno.2018.09.025","article-title":"Does methotrexate (MTX) dosing in a 8-day MTX\/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study","volume":"151","author":"Mangili","year":"2018","journal-title":"Gynecol Oncol"},{"key":"key2021111609244511_ref1-bib69","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.reprotox.2016.04.027","article-title":"Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States","volume":"62","author":"Fejzo","year":"2016","journal-title":"Reprod Toxicol"},{"key":"key2021111609244511_ref1-bib70","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1056\/NEJMoa0807154","article-title":"The safety of metoclopramide use in the first trimester of pregnancy","volume":"360","author":"Matok","year":"2009","journal-title":"N Engl J Med"},{"key":"key2021111609244511_ref1-bib71","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1001\/jama.2013.278343","article-title":"Metoclopramide in pregnancy and risk of major congenital malformations and fetal death","volume":"310","author":"Pasternak","year":"2013","journal-title":"JAMA"},{"key":"key2021111609244511_ref1-bib72","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/AOG.0000000000001388","article-title":"Ondansetron use in pregnancy and birth defects: a systematic review","volume":"127","author":"Carstairs","year":"2016","journal-title":"Obstet Gynecol"},{"key":"key2021111609244511_ref1-bib73","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1001\/jama.2018.18307","article-title":"Association of maternal first-trimester ondansetron use with cardiac malformations and oral clefts in offspring","volume":"320","author":"Huybrechts","year":"2018","journal-title":"JAMA"},{"key":"key2021111609244511_ref1-bib74","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.reprotox.2018.10.010","article-title":"First trimester ondansetron exposure and risk of structural birth defects","volume":"83","author":"Zambelli-Weiner","year":"2019","journal-title":"Reprod Toxicol"},{"key":"key2021111609244511_ref1-bib75","volume-title":"PRAC Recommendations on Signals","author":"European Medicines Agency","year":"2019"},{"key":"key2021111609244511_ref1-bib76","volume-title":"EMA Pharmacovigilance Risk Assessment Committee (PRAC), Recommendations on Signals Adopted at the 8\u201311th July Meeting. Ondansetron; Signal of Birth Defects Following In-utero Exposure During the First Trimester of Pregnancy Arising from Recent Publications","author":"UK Teratology Information Service","year":"2019"},{"key":"key2021111609244511_ref1-bib77","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/ije\/dyz255","article-title":"Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect","volume":"49","author":"Lemon","year":"2020","journal-title":"Int J Epidemiol"},{"key":"key2021111609244511_ref1-bib78","doi-asserted-by":"publisher","first-page":"e015276","DOI":"10.1136\/bmjopen-2016-015276","article-title":"Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme","volume":"7","author":"Walters","year":"2017","journal-title":"BMJ Open"},{"key":"key2021111609244511_ref1-bib79","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13063-015-0617-1","article-title":"A simple technique to identify key recruitment issues in randomised controlled trials: Q-QAT \u2013 Quanti-Qualitative Appointment Timing","volume":"16","author":"Paramasivan","year":"2015","journal-title":"Trials"},{"key":"key2021111609244511_ref1-bib80","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13063-016-1391-4","article-title":"Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet Recruitment Intervention (QRI)","volume":"17","author":"Donovan","year":"2016","journal-title":"Trials"},{"key":"key2021111609244511_ref1-bib81","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jclinepi.2018.10.004","article-title":"The QuinteT recruitment intervention supported five randomized trials to recruit to target: a mixed-methods evaluation","volume":"106","author":"Rooshenas","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"key2021111609244511_ref1-bib82","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1186\/s13063-019-3578-y","article-title":"Progression criteria in trials with an internal pilot: an audit of publically funded randomised controlled trials","volume":"20","author":"Herbert","year":"2019","journal-title":"Trials"},{"key":"key2021111609244511_ref1-bib83","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/j.1471-0528.1999.tb08426.x","article-title":"Withholding consent to participate in clinical trials: decisions of pregnant women","volume":"106","author":"Mohanna","year":"1999","journal-title":"Br J Obstet Gynaecol"},{"key":"key2021111609244511_ref1-bib84","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2288-14-10","article-title":"Factors influencing recruitment to research: qualitative study of the experiences and perceptions of research teams","volume":"14","author":"Newington","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"key2021111609244511_ref1-bib85","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cct.2018.01.003","article-title":"Clinical trials recruitment planning: a proposed framework from the Clinical Trials Transformation Initiative","volume":"66","author":"Huang","year":"2018","journal-title":"Contemp Clin Trials"},{"key":"key2021111609244511_ref1-bib86","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1744-4667.2012.00141.x","article-title":"Implementation strategies \u2013 moving guidance into practice","volume":"15","author":"Latibeaudiere","year":"2013","journal-title":"Obstet Gynaecol"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2038064","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta25630\/hta25630.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2038064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T11:58:36Z","timestamp":1692100716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta25630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":86,"journal-issue":{"issue":"63","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["10.3310\/hta25630"],"URL":"https:\/\/doi.org\/10.3310\/hta25630","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"9-2017","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"9-2020","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"2-2021","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}